Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trialEllen M. Apperloo, Hiddo J.L. Heerspink, Gozewijn D. Laverman et al.|Nature Medicine|2024Cited by 95
Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for cliniciansJelle M. Beernink, Ron T. Gansevoort, Dominique van Mil et al.|Diabetes Obesity and Metabolism|2025Cited by 19
Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKDHiddo Jan L. Heerspink, José Luis Górriz, Ellen M. Apperloo et al.|Journal of the American Society of Nephrology|2024Cited by 0
Author response for "Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians"Jelle M. Beernink, Ron T. Gansevoort, Dominique van Mil et al.|Unknown|2025Cited by 0